Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05086744
Study type Interventional
Source Novartis
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 21, 2021
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT02868060 - Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) Phase 1/Phase 2
Completed NCT04346654 - A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP Phase 2
Terminated NCT01054443 - A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP) Phase 2
Recruiting NCT04915482 - TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Phase 2/Phase 3
Completed NCT00344149 - Rituximab as Second Line Treatment for ITP Phase 3
Completed NCT04669600 - A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) Phase 2
Completed NCT01666795 - Autoantibody Specificity and Response to IVIG in ITP N/A
Recruiting NCT03951623 - The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients Phase 1
Recruiting NCT04968899 - IgIV Plus Prednisone vs High-dose Dexamethasone for ITP Phase 3
Recruiting NCT03975361 - Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE) N/A